PMID- 36878906
OWN - NLM
STAT- MEDLINE
DCOM- 20230308
LR  - 20231127
IS  - 2044-5385 (Electronic)
IS  - 2044-5385 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Mar 6
TI  - Integrated analysis of next generation sequencing minimal residual disease (MRD) 
      and PET scan in transplant eligible myeloma patients.
PG  - 32
LID - 10.1038/s41408-023-00794-x [doi]
LID - 32
AB  - Minimal residual disease (MRD) assays allow response assessment in patients with 
      multiple myeloma (MM), and negativity is associated with improved survival 
      outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in 
      combination with functional imaging remains to be validated. We performed a 
      retrospective analysis on MM patients who underwent frontline autologous stem 
      cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT with NGS-MRD 
      and positron emission tomography (PET-CT). Patients with >/= 2 MRD measurements 
      were included in a secondary analysis for sequential measurements. 186 patients 
      were included. At day 100, 45 (24.2%) patients achieved MRD negativity at a 
      sensitivity threshold of 10(-6). MRD negativity was the most predictive factor 
      for longer time to next treatment (TTNT). Negativity rates did not differ 
      according to MM subtype, R-ISS Stage nor cytogenetic risk. PET-CT and MRD had 
      poor agreement, with high rates of PET-CT negativity in MRD-positive patients. 
      Patients with sustained MRD negativity had longer TTNT, regardless of baseline 
      risk characteristics. Our results show that the ability to measure deeper and 
      sustainable responses distinguishes patients with better outcomes. Achieving MRD 
      negativity was the strongest prognostic marker and could help guide 
      therapy-related decisions and serve as a response marker for clinical trials.
CI  - (c) 2023. The Author(s).
FAU - Fonseca, Rodrigo
AU  - Fonseca R
AUID- ORCID: 0000-0001-7130-0340
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Arribas, Mariano
AU  - Arribas M
AUID- ORCID: 0000-0003-1859-7098
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Wiedmeier-Nutor, Julia E
AU  - Wiedmeier-Nutor JE
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Kusne, Yael N
AU  - Kusne YN
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Gonzalez Velez, Miguel
AU  - Gonzalez Velez M
AD  - Dignity Health Cancer Institute, Phoenix, AZ, USA.
FAU - Kosiorek, Heidi E
AU  - Kosiorek HE
AD  - Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.
FAU - Butterfield, Richard Duke J
AU  - Butterfield RDJ
AD  - Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.
FAU - Kirsch, Ilan R
AU  - Kirsch IR
AD  - Translational Medicine, Adaptive Biotechnologies, Seattle, WA, USA.
FAU - Mikhael, Joseph R
AU  - Mikhael JR
AUID- ORCID: 0000-0001-9670-2864
AD  - Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, 
      AZ, USA.
FAU - Stewart, A Keith
AU  - Stewart AK
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
FAU - Reeder, Craig
AU  - Reeder C
AUID- ORCID: 0000-0002-7158-0669
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Larsen, Jeremy
AU  - Larsen J
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Bergsagel, P Leif
AU  - Bergsagel PL
AUID- ORCID: 0000-0003-1523-7388
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Fonseca, Rafael
AU  - Fonseca R
AUID- ORCID: 0000-0002-5938-3769
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. 
      fonseca.rafael@mayo.edu.
LA  - eng
GR  - P30 CA015083/CA/NCI NIH HHS/United States
GR  - P50 CA186781/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230306
PL  - United States
TA  - Blood Cancer J
JT  - Blood cancer journal
JID - 101568469
SB  - IM
EIN - Blood Cancer J. 2023 May 26;13(1):87. PMID: 37230980
MH  - Humans
MH  - *Multiple Myeloma/diagnostic imaging/genetics/therapy
MH  - Positron Emission Tomography Computed Tomography
MH  - High-Throughput Nucleotide Sequencing
MH  - Neoplasm, Residual
MH  - Retrospective Studies
MH  - Positron-Emission Tomography
PMC - PMC9988896
COIS- JRM: has served as a consultant for Amgen, BMS, Janssen, Karyopharm and Sanofi. 
      IRK is a full time employee of Adaptive Biotechnologies. AKS: has served as a 
      consultant for Skyline, Tempus; also has a patent for cereblon as a biomarker 
      issued and is found of a company called PIKSci Inc. PLB: has served as a 
      consultant for Pfizer, Novartis, GSK, Janssen and Oncopeptides. RF: has served as 
      a consultant for AbbVie, Amgen, Bayer, BMS/Celgene, GSK, H3 Therapeutics, 
      Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Oncopeptides, Oncotracker, 
      Pfizer, Pharmacyclics, Regeneron, Sanofi, Takeda; and has served as an advisory 
      board member for Adaptive Biotechnologies, Caris Life Sciences and OncoMyx. No 
      disclosures were reported by the other authors.
EDAT- 2023/03/07 06:00
MHDA- 2023/03/09 06:00
PMCR- 2023/03/06
CRDT- 2023/03/06 23:13
PHST- 2022/10/07 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/01/26 00:00 [revised]
PHST- 2023/03/06 23:13 [entrez]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/09 06:00 [medline]
PHST- 2023/03/06 00:00 [pmc-release]
AID - 10.1038/s41408-023-00794-x [pii]
AID - 794 [pii]
AID - 10.1038/s41408-023-00794-x [doi]
PST - epublish
SO  - Blood Cancer J. 2023 Mar 6;13(1):32. doi: 10.1038/s41408-023-00794-x.